The ALFA project: A research platform to identify early pathophysiological features of Alzheimer's disease

Molinuevo, José Luis; Gramunt Fombuena, Nina; Gispert, Juan Domingo; Fauria, Karine; Esteller, Manel; Minguillón, Carolina; Sánchez Benavides, Gonzalo; Huesa, Gema; Morán, Sebastián; Dal-Ré, Rafael; Camí, Jordi, 1952-

doi:http://dx.doi.org/10.1016/j.trci.2016.02.003

The ALFA project: A research platform to identify early pathophysiological features of Alzheimer's disease

License

Citation

Molinuevo JL, Gramunt N, Domingo Gispert J, Fauria K, Esteller M, Minguillon C et al. The ALFA project: A research platform to identify early pathophysiological features of Alzheimer's disease. Alzheimer's & Dementia. 2016;2(2):82-92. DOI: 10.1016/j.trci.2016.02.003

Abstract

Introduction: The preclinical phase of Alzheimer's disease (AD) is optimal for identifying early pathophysiological events and developing prevention programs, which are shared aims of the ALFA project, including the ALFA registry and parent cohort and the nested ALFA+ cohort study. Methods: The ALFA parent cohort baseline visit included full cognitive evaluation, lifestyle habits questionnaires, DNA extraction, and MRI. The nested ALFA+ study adds wet and imaging biomarkers for deeper phenotyping. Results: A total of 2743 participants aged 45 to 74 years were included in the ALFA parent cohort. We show that this cohort, mostly composed of cognitively normal offspring of AD patients, is enriched for AD genetic risk factors. Discussion: The ALFA project represents a valuable infrastructure that will leverage with different studies and trials to prevent AD. The longitudinal ALFA+ cohort will serve to untangle the natural history of the disease and to model the preclinical stages to develop successful trials.